Genome & Company doses patients in immuno-oncology microbiome therapeutic trial

By The Science Advisory Board staff writers

October 27, 2020 -- Genome & Company has initiated clinical testing of GEN-001, an anti-cancer microbiome therapeutic, six months after its investigational new drug approval.

The phase Ib clinical trial will evaluate the oral microbiology therapy candidate in combination with avelumab (Bavencio), an anti-programmed cell death ligand 1 (PD-L1) checkpoint inhibitor in patients with a variety of solid tumors. Bavencio is being jointly developed by Merck and Pfizer.

A total of three trial centers including Oregon Health and Science University Knight Cancer Institute will complete the dose escalation cohort in the first half of 2021.

Under the agreement, Genome & Company will sponsor the study and Merck and Pfizer will supply Bavencio for the phase I/IB clinical trial.

Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat...
Bristol Myers Squibb advances cancer immunotherapy in Europe
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb's nivolumab (Opdivo).
EpiMorgify algorithm predicts best conditions for cell therapies
In order to determine optimal cell growth conditions for the development of cellular therapies, researchers have devised an algorithm called EpiMorgify...
Targovax granted European patent for cancer immunotherapy
The European Patent Office has granted a patent to clinical stage immuno-oncology firm Targovax for use of its modified adenovirus in combination with...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter